Ximbio reagent trading portal increases portfolio by over 40% in first year
Ximbio committed to antibody reproducibility and open source information
London, UK, 02 November 2015: Ximbio (www.ximbio.com), an online reagents portal for the life science community which originates from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK, has increased the number of reagents in its portfolio by 42% since the website launched in October last year. The company now has more than 20 research institutes from the UK, Europe and the USA enlisted to virtually deposit their reagents.
Ximbio provides a portal for the life science community to exchange knowledge and trade reagents. Researchers and technology transfer offices can virtually upload their reagents to the Ximbio website. Bench scientists can make informed decisions about which reagents to use, though the Ximbio searchable database, extensive datasheets, peer reviews and supplier options. Each reagent record can be linked to the originating inventor, enabling scientists and institutions to raise the profile of their work.
All reagents listed on Ximbio are supported with originating data on the generation and validation of the tool. There are now over 2,500 peer-reviewed references, linked to 1,401 reagents, which are accessible to every user.
“In recent months, we have seen an increased awareness across the research community for the need for data reproducibility. Scientists are becoming more critical of the antibodies and other reagents they are using, and access to characterisation data is something that more researchers are asking for. At Ximbio we are committed to both antibody reproducibility, and open source information, which is why we ensure all new reagents listed on the website have supporting data or a peer reviewed journal showing how the tool was created or validated.” commented Melanie Hardman, Head of Ximbio.
Life science companies can use Ximbio to easily source new products to augment their portfolios via a straightforward commercialisation process. The company has a global reach, with over 200 suppliers and biotech companies licensing products through Ximbio, from the US, Europe, Asia and Australia.
ENDS
Notes to Editors:
Photo: Melanie Hardman, Head of Ximbio. For a high resolution image please contact lorna.cuddon@zymecommunications.com
Media contacts:
Zyme Communications Ltd.
Lorna Cuddon / Katie Odgaard
e-mail: lorna.cuddon@zymecommunications.com/katie.odgaard@zymecommunications.com
Tel: +44 (0)7811 996 942 / +44 (0)7787 502 947
About Ximbio (www.ximb.io)
Ximbio is a website that has been created to enable exchange of knowledge and trading of reagents such as mouse models, antibodies, cell lines and small molecules. It is also a marketplace to maximise commercial opportunities for these tools. Our mission is to unify the life science community to make research tools widely available and accelerate research.
Through Ximbio, researchers and technology transfer offices can virtually upload their reagents. Each reagent can be linked to the originating inventor, enabling scientists and institutions to raise the profile of their work.
Life science reagents companies can use Ximbio to easily source new products to augment their portfolios via a straightforward commercialisation process.
Bench scientists can make informed decisions about which reagents to use, though the Ximbio searchable database, extensive datasheets, peer reviews and supplier options.
Ximbio originates from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK. The team behind Ximbio has more than 25 years’ experience in commercialising reagents. Ximbio provides access to research tools focussed on all areas of biology, not just cancer.
About Cancer Research Technology
Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research.